Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313722 | 0.91 | KCNH2 (0.71) | HTR2AKCNH2KDM4ECYP1A2CYP3A4 | |
| SCHEMBL11747892 | 0.86 | KCNH2 (0.64) | HTR2AKCNH2MEN1LMNAKMT2A | |
| SCHEMBL7328197 | 0.85 | HTR2A (0.72) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24135454 | 0.84 | KCNH2 (0.79) | HTR2AKCNH2KDM4ECYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL8403779 | 0.84 | HTR2A (0.71) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7250766 | 0.83 | KCNH2 (0.72) | HTR2AKCNH2KDM4ECYP1A2CYP3A4 | |
| SCHEMBL7839803 | 0.83 | HTR2A (1.00) | HTR2AKCNH2KDM4ECYP1A2CYP3A4 | |
| SCHEMBL6344464 | 0.83 | HTR2A (0.73) | HTR2AKCNH2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7828801 | 0.82 | HTR2A (0.97) | HTR2AKCNH2KDM4ECYP1A2CYP3A4 | |
| SCHEMBL14638289 | 0.81 | HTR2A (0.66) | HTR2AKCNH2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108069956-B | 1-azabicyclo [2,2,2] oct-4-yl phenyl ketone compound, preparation method and application thereof | 扬州奥锐特药业有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-108069956-A | 1- azabicyclos [2,2,2] octyl- 4- base phenyl ketone compounds and its preparation method and application | 扬州奥锐特药业有限公司 | 2018-05-25 | — | — | CN | claimed |
| EP-3630756-B1 | PROCESS FOR THE PREPARATION OF AN UMECLIDINIUM SYNTHESIS INTERMEDIATE | OLON SPA (IT) | 2021-12-29 | — | — | EP | disclosed |
| US-11028082-B2 | Process for the preparation of a novel umeclidinium synthesis intermediate | OLON S.P.A. (IT) | 2021-06-08 | — | — | US | disclosed |
| CN-108069956-B | 1-azabicyclo [2,2,2] oct-4-yl phenyl ketone compound, preparation method and application thereof | 扬州奥锐特药业有限公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-108069956-B | 1-azabicyclo [2,2,2] oct-4-yl phenyl ketone compound, preparation method and application thereof | 扬州奥锐特药业有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3630756-A1 | PROCESS FOR THE PREPARATION OF A NOVEL UMECLIDINIUM SYNTHESIS INTERMEDIATE | OLON S.p.A. (IT) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102300-A1 | PROCESS FOR THE PREPARATION OF A NOVEL UMECLIDINIUM SYNTHESIS INTERMEDIATE | OLON S.P.A. (IT) | 2020-04-02 | — | — | US | disclosed |
| WO-2018220501-A1 | PROCESS FOR THE PREPARATION OF A NOVEL UMECLIDINIUM SYNTHESIS INTERMEDIATE | OLON S.P.A. (IT) | 2018-12-06 | — | — | WO | disclosed |
| CN-108069956-A | 1- azabicyclos [2,2,2] octyl- 4- base phenyl ketone compounds and its preparation method and application | 扬州奥锐特药业有限公司 | 2018-05-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028082-B2 | Process for the preparation of a novel umeclidinium synthesis intermediate | UMPS, UROD, UGP2 | HTR2A 4515/4885KCNH2 1117/4885KDM4E 764/4885 |
| US-20200102300-A1 | PROCESS FOR THE PREPARATION OF A NOVEL UMECLIDINIUM SYNTHESIS INTERMEDIATE | UMPS, UROD, UGP2 | HTR2A 4515/4885KCNH2 1117/4885KDM4E 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.